Scientists are leveraging cutting-edge organoid technology to uncover the causes of Parkinson's and accelerate the development of new treatments. Study: Human midbrain organoids: a powerful tool for advanced Parkinson’s disease modeling and therapy exploration . Image Credit: mi_viri/Shutterstock.
com In a recent review published in the npj Parkinsons Disease , a group of authors explored the use of human midbrain organoids (mini 3D organ models) in Parkinson’s disease (PD) (movement disorder) research, drug screening, and therapy, highlighting challenges and optimization strategies. Background PD is a common neurodegenerative disorder affecting over 6.1 million people globally, characterized by motor symptoms like tremors, bradykinesia (slow movement), and rigidity, as well as non-motor issues such as depression and cognitive decline.
The loss of midbrain dopaminergic neurons and the presence of Lewy Bodies, made of abnormal α-synuclein protein, are hallmarks of PD. Current research tools, including post-mortem brain tissue, animal models, and cell cultures, have limitations. Further research is needed to develop better human-relevant models to understand PD mechanisms and improve treatment options.
Midbrain organoids and PD Over the past decade, the rise of three-dimensional (3D) organoid technology has revolutionized stem cell research. Organoids, which are miniature, in vitro 3D cellular structures derived from induced pluripotent stem cells (iPSCs) or isolated progen.
